Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998146 | 1.00 | CCR1 (0.71) | CCR1ABCB11LMNAKDM4EALDH1A1 | |
| SCHEMBL4998451 | 0.91 | CCR1 (0.58) | CCR1ABCB11LMNAKDM4EALDH1A1 | |
| SCHEMBL2061814 | 0.90 | CCR1 (0.74) | CCR1ABCB11LMNAALDH1A1MEN1 | |
| Azd4818 SCHEMBL3677057 | 0.88 | CCR1 (0.83) | CCR1ABCB11LMNAKDM4EALDH1A1 | |
| SCHEMBL14093756 | 0.85 | CCR1 (0.85) | CCR1ABCB11MEN1KMT2AMCHR1 | |
| SCHEMBL3677535 | 0.84 | CCR1 (0.72) | CCR1ABCB11LMNAKDM4EALDH1A1 | |
| Azd4818 SCHEMBL4377890 | 0.84 | CCR1 (1.00) | CCR1ABCB11MEN1KMT2AMCHR1 | |
| Azd4818 SCHEMBL523439 | 0.84 | CCR1 (1.00) | CCR1ABCB11MEN1KMT2AMCHR1 | |
| Azd4818 SCHEMBL29395913 | 0.84 | CCR1 (1.00) | CCR1ABCB11MEN1KMT2AMCHR1 | |
| SCHEMBL4998445 | 0.82 | ABCB11 (0.69) | CCR1ABCB11LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280951-A1 | Salt Il | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| EP-1922074-B1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA. | ASTRAZENECA AB (SE) | 2010-02-17 | — | — | EP | disclosed |
| US-20090298875-A1 | A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20080280951-A1 | Salt Il | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-20080280951-A1 | Salt Il | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| CN-101238102-A | Novel salt II | ASTRAZENECA AB (SE) | 2008-08-06 | — | — | CN | disclosed |
| EP-1922305-A1 | NEW SALT II | AstraZeneca AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1922305-A1 | NEW SALT II | AstraZeneca AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1922070-A1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1922074-A1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA. | AstraZeneca AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007024182-A1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA. | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024183-A1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007015667-A1 | NEW SALT II | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015667-A1 | NEW SALT II | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | NR3C1, NR3C2, CHRM3 | CCR1 71/4885ABCB11 1725/4885LMNA 3843/4885 |
| US-20080280951-A1 | Salt Il | IL2, IL4, IL5 | CCR1 135/4885ABCB11 2217/4885LMNA 4275/4885 |
| US-20090298875-A1 | A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ADRB2, ADRB1, CHRM2 | CCR1 242/4885ABCB11 2624/4885LMNA 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.